🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Characterization and Longitudinal Monitoring of Muscular Phenotype in Patients Admitted to Intensive Care for Sepsis

RecruitingNAAges 18 Years - anyAllCentre Hospitalier de Saint-Brieuc
NCT07074028 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Approximately 40% of patients develop muscle dysfunction during their stay in intensive care, particularly in the context of sepsis. This dysfunction represents an acquired muscle injury that is secondary to the primary illness that led to ICU admission. It affects both the limb muscles and the respiratory muscles of the thoracic cage. Clinically, this manifests as bilateral and symmetrical muscle weakness in the limbs, and contributes significantly to difficulties in weaning patients off mechanical ventilation. The loss of muscle mass is directly correlated with the severity of the patient's clinical condition and can reach up to 20% of initial muscle mass within just ten days. This rapid and profound atrophy primarily results from an imbalance between increased muscle protein breakdown (catabolism) and insufficient protein synthesis (anabolism). The consequences of this muscle dysfunc

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants admitted to ICU with an expected length of stay greater than 7 days. * Expected duration of invasive mechanical ventilation greater than 48 hours. * Diagnosis of sepsis upon ICU admission (presence of an infection and a SOFA score ≥ 2, or an increase of ≥ 2 points if organ dysfunction was present prior to infection). * Informed consent obtained from the participant or from a designated surrogate decision-maker Exclusion Criteria: * Pregnant women. * Participants not affiliated with the national health insurance system. * Participants under legal protection (guardianship or conservatorship). * Moribund participants (end-of-life patients). * Participants with active cancer. * Participants with chronic neuromuscular disorders or admitted to the ICU for an acute neuromuscular condition.
💊

What it tests

  • Medical Research Council sum score (MRC-SS) test
  • Handgrip test combined with surface electromyography (sEMG)
  • Electrical activity during maximal voluntary contraction of the rectus femoris
  • Musculoskeletal Ultrasound
  • Diaphragmatic ultrasound
📍

Where

1 site
Centre Hospitalier de Saint-Brieuc - Paimpol - Tréguier
Saint-Brieuc, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy